Amgen Shares Plunge After Weight-Loss Drug Misses Expectations | News Today | AF14 [bd4ipjZznc3]

Amgen Shares Plunge After Weight-Loss Drug Misses Expectations | News Today | AF14 [bd4ipjZznc3]

| 1h 28m 28s | Video has closed captioning.

Amgen shares experienced their steepest decline in over two decades as results from their experimental weight-loss drug, MariTide, failed to surpass Wall Street's high expectations. Despite showing promise with an average 20% weight loss in a year-long trial, analysts noted MariTide’s results were only on par with drugs already approved from Novo Nordisk and Eli Lilly, such as Ozempic, Wegovy, and Mounjaro. Amgen's drug also showed slightly higher side effects, contributing to the market’s disappointment. Amgen Shares Plunge After Weight-Loss Drug Misses Expectations | News Today | AF14 #Amgen #MariTide #WeightLoss #StockMarket #NovoNordisk #EliLilly #Ozempic #Medicare #Medicaid #Biotech Talks Shows Central brings the latest in news, lifestyle programs, comic and political Talk Shows, Such as, Black & White, Nadeem Malik Live, Red Line, Gup Shab Nay Had Kar Di and more to your screens. Subscribe and never stay behind on the newest developments from across the country Talk Shows Central YouTube Channel is managed by Dot Republic Media, All Copyrights Reserved. Subscribe to our channel for all the latest updates: Like our Facebook page: #who sell keto gummies #is keto luxe gummies legit #stein medical weight loss